Relmada Therapeutics (NASDAQ:RLMD) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Relmada Therapeutics (NASDAQ:RLMD) issued its quarterly earnings results on Thursday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.13), Zacks reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

• NDV?01 phase II 12?month data reported a 76% 12?month complete response rate overall and 80% in BCG?unresponsive patients (CR anytime 95% overall, 94% BCG?unresponsive) with a favorable safety profile (no progression to muscle?invasive disease, no cystectomies, no grade ?3 treatment?related AEs).
• Relmada secured FDA alignment on a two?pathway registrational strategy and plans to initiate the phase III RESCUE program mid?2026—an adjuvant randomized trial in intermediate?risk NMIBC (vs observation) and a single?arm BCG?unresponsive trial, with initial 3?month readouts expected by end?2026.
• The company completed a $160M private financing and reported $93M cash at year?end 2025, which management states provides runway through 2029 and to complete the NDV?01 phase III program.
• Q4 2025 results showed a net loss of $19.9M ($0.27/sh) and higher operating cash burn (net cash used in operations $14.6M in Q4) with increased G&A expenses, reflecting continued development?stage losses.
• Sepranolone (a GABA?modulating steroid antagonist) is advancing toward a mid?2026 proof?of?concept trial in Prader?Willi, but these are company forward?looking statements and remain subject to clinical and regulatory risks.

Relmada Therapeutics Stock Up 0.6%

Shares of RLMD opened at $6.25 on Friday. Relmada Therapeutics has a 52-week low of $0.24 and a 52-week high of $7.51. The company has a 50-day simple moving average of $4.47 and a 200-day simple moving average of $3.53. The company has a market capitalization of $458.31 million, a PE ratio of -3.47 and a beta of 0.72.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC acquired a new stake in shares of Relmada Therapeutics during the 4th quarter valued at approximately $668,000. Two Sigma Investments LP grew its holdings in shares of Relmada Therapeutics by 82.0% in the 3rd quarter. Two Sigma Investments LP now owns 173,614 shares of the company’s stock worth $349,000 after acquiring an additional 78,197 shares during the period. ExodusPoint Capital Management LP acquired a new stake in shares of Relmada Therapeutics in the 4th quarter worth approximately $333,000. OMERS ADMINISTRATION Corp purchased a new position in Relmada Therapeutics in the 4th quarter valued at approximately $318,000. Finally, Quadrature Capital Ltd purchased a new position in Relmada Therapeutics in the 4th quarter valued at approximately $258,000. 45.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on RLMD. Zacks Research upgraded shares of Relmada Therapeutics to a “hold” rating in a research report on Tuesday, January 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Relmada Therapeutics in a research note on Wednesday, January 28th. Mizuho set a $10.00 price target on shares of Relmada Therapeutics in a report on Friday, March 13th. Lucid Cap Mkts upgraded shares of Relmada Therapeutics to a “strong-buy” rating in a research report on Monday, March 2nd. Finally, Leerink Partners raised Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 price objective on the stock in a report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Relmada Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.